Dow Down0.36% Nasdaq Down0.53%

Progenics Pharmaceuticals, Inc. (PGNX)

-NasdaqGS
5.27 Down 0.15(2.77%) Sep 12, 4:00PM EDT
|After Hours : 5.25 Down 0.02 (0.38%) Sep 12, 6:47PM EDT
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
Total Revenue 7,862   14,048   84,796  
Cost of Revenue567  1,170  578  
Gross Profit 7,295   12,878   84,218  
Operating Expenses
Research Development33,903  31,840  53,183  
Selling General and Administrative14,809  14,706  18,248  
Non Recurring624  499  405  
Others939  1,324  2,066  
Total Operating Expenses50,275  48,369  73,902  
Operating Income or Loss (42,980) (35,491) 10,316  
Income from Continuing Operations
Total Other Income/Expenses Net46  60  65  
Earnings Before Interest And Taxes(42,934)(35,431)10,381  
Interest Expense -   -   -  
Income Before Tax(42,934)(35,431)10,381  
Income Tax Expense(362) -   -  
Minority Interest -   -   -  
Net Income From Continuing Ops(42,572)(35,431)10,381  
Non-recurring Events
Discontinued Operations -   -   -  
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income (42,572) (35,431) 10,381  
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares (42,572) (35,431) 10,381  

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.